Our work on detection of malignancies in body fluids such as bronchial lavages, pleural fluids, peritoneal fluids, and fine needle aspirates as published on Genome Medicine as a follow-up to our Nature Medicine metagenomics work. Similar work using CSF for CNS tumor is posted on Medrxiv.
Our work on rapid metagenomic testing of infected body fluids using cell-free DNA was published in Nature Medicine.
Our work on DASH was featured by IDT. As the first demonstration of using CRISPR-Cas as a tool for in vitro diagnostics, DASH is a compelling approach for targeting and depleting unwanted background in low input specimens.
Our work on early USA transmission of SARS-2-CoV using viral phylogenetics has been published in Science (paper 1, paper 2) and Clinical Infectious Disease, and featured in WSJ, NYTimes (Article 2), LATimes, SF Chronicle, USA Today.
Proud to have collaborated with many other labs to develop a multitude of novel rapid SARS-2-CoV testing, now published in Nature Biotech (paper 1, paper 2), Cell Med, Cell Reports Med, Nature Comm, and featured in NYTimes, SF Chronicle, WSJ, STAT, NPR.
We are grateful to the National Cancer Institute and the Burroughs Wellcome Fund for their support.
Support our research on minimally invasive diagnostics or other breakthrough research at Stanford. To donate to our work, mention: Gu Lab, Dept. of Pathology.
Stanford University is committed to providing an online environment that is accessible to everyone, including individuals with disabilities.
Having trouble accessing any of this content due to a disability? Learn more about accessibility at Stanford and report accessibility issues
The Gu Lab is committed to creating an inclusive environment and is proud to be an equal opportunity employer.